WILMINGTON, Del., April 2, 2026
Earendil Labs, an AI-driven biotechnology company, has announced that the first patient has been dosed in its Phase IIa clinical trial of HXN-1001, a half-life extended anti-TL1A monoclonal antibody, for the treatment of ulcerative colitis, marking a key milestone in the development of next-generation biologics for inflammatory bowel disease (IBD). The company also confirmed the successful completion of its Phase I clinical trial in healthy volunteers, demonstrating a favorable safety profile, extended half-life, and strong pharmacokinetic characteristics, positioning HXN-1001 as a promising candidate in the rapidly evolving immunology therapeutics landscape.
Phase IIa Trial Evaluates Safety and Early Efficacy
The ongoing Phase IIa clinical trial is a randomized, placebo-controlled study designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of HXN-1001 in patients with ulcerative colitis, a chronic inflammatory condition of the gastrointestinal tract. The initiation of dosing represents a critical step in transitioning from early-stage clinical validation to patient-focused therapeutic evaluation, where efficacy signals begin to emerge.
Ulcerative colitis remains a significant unmet medical need, with many patients experiencing inadequate response or loss of response to existing therapies, including biologics and small molecules. By targeting the TL1A pathway, a key regulator of inflammation, HXN-1001 aims to provide a novel mechanism of action that could improve disease control and long-term outcomes.
Next-Generation Anti-TL1A Antibody Shows Strong Profile
Advertisement
HXN-1001 is a next-generation monoclonal antibody engineered with an extended half-life of approximately 8 weeks, allowing for less frequent dosing and improved patient convenience. In Phase I studies, the therapy demonstrated good tolerability across multiple dose levels, including single doses up to 1200 mg and repeated dosing regimens, with a low incidence of anti-drug antibodies, indicating strong immunogenicity control.
Preclinical studies further showed that HXN-1001 exhibited enhanced potency compared to benchmark therapies currently in development, supporting its potential as a best-in-class biologic. Additionally, the formulation is optimized for high-concentration subcutaneous administration, enabling more convenient outpatient treatment options compared to traditional intravenous therapies.
AI-Driven Biologics Platform Accelerates Innovation
Earendil Labs leverages an AI-native drug discovery platform to accelerate the development of protein-based therapeutics, integrating machine learning and computational biology across the full research and development lifecycle. This approach enables the company to rapidly design, optimize, and advance biologics with improved efficacy, safety, and manufacturability, reducing development timelines and increasing success rates.
The advancement of HXN-1001 reflects the growing impact of artificial intelligence in biologics innovation, particularly in complex disease areas such as autoimmune disorders and inflammatory diseases. As the company continues to expand its pipeline, it aims to deliver transformative therapies that address critical unmet needs in global healthcare.
With the initiation of Phase IIa dosing and strong early clinical data, Earendil Labs is positioning HXN-1001 as a potential next-generation therapy for ulcerative colitis and broader IBD indications, combining innovative biology with AI-driven drug development to advance the future of precision medicine and immunology therapeutics.
Source: Earendil Labs press release
